Q-omics provides the consensus-scored IL2RG profile across patient tissues and cancer cell-line models. IL2RG expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, IL2RG is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, IL2RG RNA expression shows 19,103 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight HNSC, KIRC, and LSCC as cancer lineages where IL2RG shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for IL2RG — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes IL2RG survival associations across molecular data types. IL2RG RNA expression shows survival associations in the most cancer types (27), followed by mutation status (2) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible IL2RG RNA expression–survival associations across cancer types. High IL2RG expression shows unfavorable associations in UVM and LGG, but favorable associations in HNSC, SKCM, UCEC and BRCA. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for IL2RG RNA expression.
This table summarizes IL2RG tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 2. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for IL2RG. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. IL2RG shows lower tumor expression in KICH, LUSC and COAD and higher tumor expression in KIRC, STAD and BRCA. The KIRC box plot shows higher IL2RG RNA expression in tumor versus normal tissue (log2 FC = +1.862, t-test p < 0.001).
This table shows molecular features associated with IL2RG in patient tissues and cancer cell lines. In patient samples, IL2RG shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, IL2RG RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Myeloma, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and LARGE_INTESTINE.
